Issue 18, 2025

Synthesis, molecular docking, pharmacological evaluation, MD simulation, and DFT calculations of quinazolin-12-one derivatives as PDK1 inhibitors

Abstract

3-Phosphoinositide-dependent protein kinase-1(PDK1) is a vital kinase in cellular signaling that regulates growth and survival, playing a crucial role in cancer by activating Akt within the PI3K/Akt pathway. Elevated PDK1 levels correlate with tumor progression and chemotherapy resistance, highlighting its potential as a therapeutic target and biomarker. Schiff bases (SBs) are widely utilized as anticancer agents, as well as for antiviral, antipyretic, antimicrobial, antifungal, antiproliferative, and anti-inflammatory purposes. In this study, we synthesized a series of new quinazolin-12-one derivatives with moderate to good yields (72–92%) and evaluated their efficacy against PDK1 using in silico methods. Comprehensive computational studies, including quantum chemical calculations, molecular docking, molecular dynamics (MD), and absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiling, were performed. Density functional theory (DFT) analysis with the B3LYP/6-31++G (d, p) basis set indicated a promising reactivity profile for the synthesized compounds. The oxygen atoms and π-system of the title compound exhibit high chemical reactivity, serving as electron donor sites and targets for electrophilic attack. Docking analysis with PDK1 enzymes revealed that all compounds, with docking scores between −9.99 and −10.44, demonstrated greater binding affinity than the native ligand, which had a score of −9.49. Among these, compound 3f, with an energy of −10.44 kcal mol−1, displayed the strongest binding affinity. The MD simulation showed that Ala162 stands out with a notably high interaction fraction, suggesting that it may be a critical residue for the binding affinity of compound 3f. The analysis of ADMET properties indicated that all inhibitor compounds exhibit favorable pharmacological characteristics, including adherence to Lipinski's Rule of Five (Ro5) as well as the Ghose, Veber, and Egan rules. Additionally, the physicochemical properties demonstrate that all synthesized compounds are capable of human intestinal absorption and have the ability to penetrate the blood–brain barrier (BBB).

Graphical abstract: Synthesis, molecular docking, pharmacological evaluation, MD simulation, and DFT calculations of quinazolin-12-one derivatives as PDK1 inhibitors

Supplementary files

Article information

Article type
Paper
Submitted
24 Feb 2025
Accepted
21 Jul 2025
First published
12 Aug 2025
This article is Open Access
Creative Commons BY-NC license

Nanoscale Adv., 2025,7, 5760-5783

Synthesis, molecular docking, pharmacological evaluation, MD simulation, and DFT calculations of quinazolin-12-one derivatives as PDK1 inhibitors

Z. Sadeghian, M. Bayat and D. Gheidari, Nanoscale Adv., 2025, 7, 5760 DOI: 10.1039/D5NA00182J

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements